Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Warner-Lambert Merger Talks Begin: AHP Vows To Press On

Executive Summary

The merger negotiations between Warner-Lambert and Pfizer are likely to focus on the $1 bil. gap between Pfizer's offer and Warner's current stock market valuation.

You may also be interested in...



P&G Merger Talks May Herald Next Step In Consumer-Focused Rx Marketing

Procter & Gamble's aborted merger discussions with Warner-Lambert and American Home Products may herald the next phase in the evolution of consumer-focused pharmaceutical marketing.

P&G Merger Talks May Herald Next Step In Consumer-Focused Rx Marketing

Procter & Gamble's aborted merger discussions with Warner-Lambert and American Home Products may herald the next phase in the evolution of consumer-focused pharmaceutical marketing.

Wyeth-Ayerst's Protonix

Approval of the proton pump inhibitor pantoprazole is expected in the third quarter of 2000, American Home Products Senior VP-Science & Technology Robert Levy, MD, tells the Chase H&Q Healthcare Conference in San Francisco Jan. 11. The product is "approvable" at FDA. The company expects to be able to provide information requested by FDA from data it has already collected. AHP and Warner-Lambert have discussed a co-promotion agreement for Protonix while pursuing a merger, but Warner-Lambert has now decided to pursue merger negotiations with Pfizer (1see related story, p. 24)

Related Content

UsernamePublicRestriction

Register

PS035449

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel